Oragenics

Oragenics, Inc. is a development-stage company focused on combating infectious diseases, including coronaviruses and multidrug-resistant organisms. Our lead product is an intranasal vaccine candidate designed to provide long-term immunity against SARS-CoV-2, the virus that causes COVID-19, and its variants. The NT-CoV-2 program leverages research on coronavirus spike proteins licensed from the U.S. National Institutes of Health (NIH) and the National Research Council of Canada (NRC), with an emphasis on reducing viral transmission and offering patient-friendly intranasal administration. Our l antibiotic program features a novel antibiotic aimed at combating bacteria resistant to commercially available antibiotics.